You are here

Article info

Article menu

Download PDFPDF

XML
Research Article
Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1

Authors

  1. ↵a suzanne{at}replimune.com
  2. ↵b linta{at}replimune.com
  3. ↵c victoria.roulstone{at}icr.ac.uk
  4. ↵d joan.kyula{at}icr.ac.uk
  5. ↵e david.mansfield{at}icr.ac.uk
  6. ↵f PKB38{at}gsbs.rutgers.edu
  7. ↵g Henry.Smith{at}icr.ac.uk
  8. ↵h howard.kaufman{at}replimune.com
  9. ↵i kevin.harrington{at}icr.ac.uk
  10. ↵j Rob{at}replimune.com
View Full Text

Citation

Thomas S, Kuncheria L, Roulstone V, et al
Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1
Journal for ImmunoTherapy of Cancer 2019;7:214. doi: 10.1186/s40425-019-0682-1

Publication history

  • Received February 6, 2019
  • Accepted June 10, 2019
  • First published August 10, 2019.
Online issue publication 
August 10, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.